^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Regimen:CVbP
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/12/2023
    Excerpt:
    Pediatric Hodgkin Lymphoma….PRIMARY TREATMENT….CVbP +/- rituximab